BioXcel Therapeutics, Inc. Banner Image

BioXcel Therapeutics, Inc. has reached its limit for free report views

Work for BioXcel Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

BioXcel Therapeutics, Inc.

  • Ticker BTAI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BioXcel Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in New Haven, Connecticut
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithmsMore to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents.
4.8 / 5.0 (308)

BioXcel Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 308 reviews.

BioXcel Therapeutics, Inc.

Most Recent Annual Report

BioXcel Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. BioXcel Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

BioXcel Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!